1. Home
  2. HTT vs REPL Comparison

HTT vs REPL Comparison

Compare HTT & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo High Templar Tech Limited American depositary shares each representing one Class A ordinary share

HTT

High Templar Tech Limited American depositary shares each representing one Class A ordinary share

N/A

Current Price

$2.52

Market Cap

464.3M

Sector

Finance

ML Signal

N/A

Logo Replimune Group Inc.

REPL

Replimune Group Inc.

N/A

Current Price

$15.16

Market Cap

454.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HTT
REPL
Founded
2014
2015
Country
China
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
464.3M
454.6M
IPO Year
2017
2018

Fundamental Metrics

Financial Performance
Metric
HTT
REPL
Price
$2.52
$15.16
Analyst Decision
Hold
Analyst Count
0
9
Target Price
N/A
$5.67
AVG Volume (30 Days)
152.2K
7.4M
Earning Date
05-29-2026
05-21-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$4.14
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.88
$1.50
52 Week High
$3.91
$15.71

Technical Indicators

Market Signals
Indicator
HTT
REPL
Relative Strength Index (RSI) 46.00 66.80
Support Level $2.34 $6.99
Resistance Level $2.59 N/A
Average True Range (ATR) 0.07 1.67
MACD 0.01 0.54
Stochastic Oscillator 61.70 95.48

Price Performance

Historical Comparison
HTT
REPL

About HTT High Templar Tech Limited American depositary shares each representing one Class A ordinary share

High Templar Tech Ltd is an enabler of financial technology. High Templar is focusing on exploring business opportunities globally to satisfy clients' demand by leveraging its technology know-how and financial service capabilities. The company focus empowering financial institutions with its technological capabilities, helping them improve marketing and operational efficiency and efficiently connect their diverse financial products with online traffic.

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.

Share on Social Networks: